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Abstract The OVCAR-3 cell line expressing the long
(ObRb) and short (ObRt) isoforms of leptin receptor
mRNA was used to analyze the effect of leptin on the
expression of selected genes and proteins involved in the
cell cycle and apoptosis. OVCAR-3 cells were exposed to
2, 20, 40, and 100 ng/ml of leptin. Cell proliferation was
determined using the alamarBlue cell viability test and flow
cytometry. Apoptosis was measured using a cellular DNA
fragmentation ELISA kit. The expression of selected cell
cycle and apoptosis genes was evaluated by real-time PCR
and confirmed by western blot. The stimulatory action of
leptin on cell proliferation was observed as an increase in
cells in the S and G2/M phases. Up-regulation of genes
responsible for inducing cell proliferation and suppression
of genes responsible for inhibition of proliferation were
noted. Western blots revealed increased expression of
cyclins D and A and inhibition of p21WAF1/CIP1 protein
expression by leptin. Inhibition of DNA fragmentation was
observed under all leptin doses. Suppression of genes
involved in the extrinsic and intrinsic apoptotic pathway
was observed. Western blots illustrated decreased Bad,
TNFR1, and caspase 6 protein expression in response to
leptin treatment. Leptin promotes ovarian cancer cell line
growth by up-regulating genes and proteins responsible for
inducing cell proliferation as well as down-regulating pro-
apoptotic genes and proteins in apoptotic pathways. Results
of this study warrant examining the relationship between
the risk of ovarian cancer and elevated leptin levels in
obese women.
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Introduction
Leptin is a multifunctional peptide hormone with wide-
ranging biologic activities, including appetite regulation,
bone formation, reproductive function, and angiogenesis.
Circulating levels of leptin are strongly correlated to body
fat content and are markedly elevated in obese compared
with normal-weight individuals [1, 2]. Plasma leptin levels
have been reported to be higher in overweight and obese
women (37.7 ng/ml) than in normal-weight women
(3.92–16.9 ng/ml) [2–4]. In some obese individuals, leptin
levels can reach 100 ng/ml [5]. Interestingly, recent studies
have demonstrated that leptin stimulates growth, migration,
invasion, and angiogenesis in tumor cell models, suggest-
ing that it can promote an aggressive cancer phenotype [6,
7]. Epidemiological studies have suggested a positive
correlation between obesity and increased risk of different
cancers, including ovarian cancer [8–10]. Several studies
have addressed the possible role of leptin, the product of
the obesity gene (Ob), in ovarian cancer development and
progression [11–13]. A recent study by Uddin et al. [13]
showed a significant association between leptin receptor
(Ob-R) overexpression and poor progression-free survival
in 59.2 % of epithelial ovarian cancers. In vitro studies
have demonstrated that leptin induces proliferation in the
ovarian cancer cell line BG-1 [11, 12], and it has been
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shown to inhibit apoptosis in ovarian epithelial cancer cell
lines SKOV3 and MDAH2774 [13]. Accumulating evi-
dence indicates that leptin has an effect on ovarian cancer
growth, but information on its molecular mechanism with
respect to regulation of the cell cycle and apoptosis is
limited.
Based on the data of Choi et al. [11], who characterized
both long (ObRb) and short (ObRt) isoforms of leptin
mRNA, as well as our previous study [14] showing protein
expression of both isoforms of the leptin receptor in the
immortalized OVCAR-3 ovarian cancer cell line, we used
this cell line to analyze the effect of leptin on the expres-




RPMI 1640 medium without phenol red, fetal bovine
serum (FBS, heat-inactivated), penicillin, streptomycin,
and trypsin EDTA were obtained from PAA Laboratories
GmbH (Colbe, Germany). Human leptin, bovine serum
albumin (BSA), and trypan blue were obtained from Sigma
Chemical Co., (St. Louis, MO, USA).
Cell culture and treatments
The human ovarian epithelial carcinoma cell line OVCAR-
3 was obtained from the American Type Culture Collection
(Manassas, VA, USA). The cells were routinely cultured in
RPMI 1640 medium without phenol red supplemented with
50 U/ml penicillin, 50 lg/ml streptomycin, and 10 % v/v
heat-inactivated FBS in a humidified incubator with 5 %
CO2 at 37 C. The cells were switched to medium without
serum 24 h before each experiment.
Cell proliferation
Cell proliferation was measured using the alamarBlue cell
viability reagent (Invitrogen, Paisley, UK) according to the
manufacturer’s instructions. The cells were seeded in
96-well culture plates at a density of 1.5 9 104 cell/well
and then incubated in RPMI 1640 supplemented with 5 %
FBS as a control medium or with four different doses (2,
20, 40, and 100 ng/ml) of leptin for 24, 48, and 72 h. The
medium was changed daily, adding new medium and new
test compounds. The alamarBlue stock solution was asep-
tically added to the wells after 24, 48, and 72 h of culture
in amounts equal to 10 % of the incubation volume. Res-
azurin reduction was determined after 4 h of incubation by
measuring the fluorescence at 560 nm (excitation)/590 nm
(emission) using an FLx800 fluorescence microplate reader
(BioTek, Winooski, VT, USA).
Flow cytometry analyses
The cells were seeded in 6-well culture plates at a density
of 0.5 9 106 cell/well in RPMI 1640 supplemented with
5 % FBS as a control medium or with 40 ng/ml of leptin
for 24 and 48 h. For analysis of cell proliferation, cell
samples were stained with propidium iodide (PI). Briefly,
after centrifugation (10 min at 1,500 rpm, 4 C), the cell
pellets were adjusted to 1 9 106 cell/ml and re-suspended
in the PI staining buffer. The buffer contained
7.5 9 10-5 M PI, 10 mM Tris base, 10 mM NaCl, 700 U/l
RNase, 0.1 ml/100 ml Nonidet P-40 (all from Sigma-
Aldrich Chemical Co., St. Louis, MO, USA) and was
adjusted to pH 8.0. The re-suspended cell pellets were kept
in the buffer for 30 min in the dark at 4 C. Samples were
then analyzed in a FACScalibur flow cytometer (Becton-
Dickinson, San Jose, CA, USA) to assess the cell cycle
DNA profile. In total, 20,000 threshold events per sample
were collected and analyzed based on their FL2 fluores-
cence (emission at 585 nm, excitation at 488 nm). The
resulting data were analyzed using CellQuest Pro software
(Becton-Dickinson). Percentages of cells present in the
various phases of the cell cycle were calculated using Cell
Quest by gating for the following cell populations: A
(apoptotic cells; \2n), G1/G0 [cells in gap 1 (G1) and
entering into the quiescent phase (G0); 2n], S (cells in the
DNA synthesis phase; [2n), and G2 ? M [cells in gap 2
(G2; 4n), and entering into the mitotic phase (M; \4n)].
Bromodeoxyuridine (BrdU) incorporation assay
DNA fragmentation was determined using the Cellular
DNA Fragmentation ELISA Kit (Roche Applied Science,
Mannheim, Germany). This assay is based on the quanti-
tative detection of BrdU-labeled DNA fragments. After
exposure to BrdU for 18 h, the cells were re-seeded in
96-well culture plates at 1.5 9 104 cell/well and then
incubated in RPMI 1640 as a control medium or with leptin
at concentrations of 2, 20, 40, and 100 ng/ml. After 24 h,
DNA fragmentation was determined according to the
manufacturer’s instructions. Absorbance values were
measured spectrophotometrically at 450 nm using an
ELx808 ELISA reader (BioTek).
Real-time PCR analysis
Cells were seeded in 6-well culture plates at 1 9 106 cell/
well in RPMI 1640 supplemented with 5 % FBS (for cell
cycle analysis) or without serum (for apoptosis analysis) as
the control medium, or with 40 ng/ml of leptin for 24 h.
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The choice of this dose was based on previous cell pro-
liferation experiments. Total RNA from OVCAR-3 cells
was isolated using the High Pure RNA Isolation Kit (Roche
Applied Science). RNA purity and quantity were deter-
mined spectrophotometrically according to optical densi-
ties at 260 and 280 nm. cDNA synthesis was performed
using the Transcriptor First Strand cDNA Synthesis Kit
(Roche Applied Science) with a mixture of anchored-oli-
go(dT)18 primers and random hexamer primers according
to the manufacturer’s protocol. Amplifications were per-
formed in duplicate using the LightCycler 480 System
(Roche Applied Science) and the Real-Time Ready Human
Apoptosis Panel and Real-Time Ready Human Cell Cycle
Regulation Panel (Roche Applied Science) in combination
with the LightCycler 480 Probes Master (Roche Applied
Science) according to the manufacturer’s instructions. PCR
was performed in a final volume of 20 ll, including 50 ng
cDNA per reaction. The PCR conditions were as follows:
pre-incubation for 10 min at 95 C, amplification for 45
cycles (10 s at 95 C, 30 s at 60 C, and 1 s at 72 C). A
positive control (to check for RNA degradation) and neg-
ative control (to detect residual genomic DNA) were run
simultaneously with every assay according to the manu-
facturer’s protocol. The relative expression of the analyzed
genes was normalized to seven reference genes in the panel
using the E-Method from Roche Applied Science, which
analyzes the amplification efficiency of target and refer-
ence genes using relative standards. These standards are
serial dilutions of a single sample (for example, undiluted,
1:10, 1:100, and so on), where the concentration is
expressed in relative units (for example, 1, 0.1, 0.01, and so
on). Using dilutions to generate a standard curve, the
E-Method avoids the time-consuming preparation of arti-
ficial or cloned standards and the determination of their
absolute values [15].
Western blot analysis
The cells were seeded in 24-well culture plates at 1 9 105
cell/well in RPMI 1640 supplemented with 5 % FBS (for
cell cycle analysis) or without serum (for apoptosis anal-
ysis) as the control medium, or with leptin at 40 ng/ml for
24 and 48 h. The cells were washed with ice-cold PBS and
lysed in ice-cold buffer. The protein concentration of the
cell lysate was determined by Bradford reagent (Bio-Rad
Protein Assay, Bio-Rad Laboratories, Munchen, Germany).
Protein (30 lg from each treatment group) was separated
by 10 and 15 % SDS-PAGE and transferred to PVDF
membranes using a Bio-Rad Mini-Protean 3 apparatus
(Bio-Rad Laboratories). The blots were blocked for 2 h
with 5 % w/v BSA and 0.1 % v/v Tween 20 in 0.02 M Tris
Buffered Saline buffer (TBS). The blots were incubated
overnight at 4 C with antibodies specific for cyclin D1,
cyclin A, p21 Waf1/Cip1, TNFR1, caspase 6, and Bad
from Cell Signaling Technology (Danvers, MA, USA).
Loading controls consisted of immunoblotting the same
membranes with b-actin antibody (Sigma Chemical Co.,).
After incubation with the primary antibody, the membranes
were washed three times and incubated for 1 h with a
horseradish peroxidase-conjugated secondary antibody
from Cell Signaling Technology for cyclin D1, cyclin A,
p21 Waf1/Cip1, TNFR1, caspase 6, and Bad (from Dako-
Cytomation, Glostrup, Denmark) for b-actin. Immunopos-
itive bands were visualized using Western Blotting
Luminol Reagents (Santa Cruz Biotechnology Inc., Santa
Cruz, CA, USA) and quantified using densitometry anal-
ysis (EasyDens, Cortex Nowa, Poland).
Statistical analysis
Data were expressed as mean ± SEM from four indepen-
dent experiments performed in triplicate. Statistical anal-
yses were performed using GraphPad Prism 5. Data were
analyzed by one-way analysis of variance (ANOVA) fol-
lowed by Tukey’s honestly significant difference (HSD)
multiple range test. A value of P \ 0.05 was considered
statistically significant.
Results
Cell proliferation (alamarBlue assay)
Growth of OVCAR-3 cells in response to various doses of
leptin was tested for 24, 48, and 72 h. An increase in cell
proliferation was noted under all leptin doses at 48 h of
treatment (1.3-fold; P \ 0.05; Fig. 1), with 2 and 20 ng/ml
of leptin at 72 h of treatment (1.3-fold; P \ 0.05; Fig. 1),
Fig. 1 Effects of leptin on OVCAR-3 cell proliferation. The cells
were treated with leptin at 2, 20, 40, and 100 ng/ml for 24, 48, and
72 h and then analyzed using the alamarBlue assay. Values are
mean ± SEM. *,***Significantly different from control at P \ 0.05
and P \ 0.001, respectively
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and with 40 and 100 ng/ml of leptin at 72 h of treatment
(1.6-fold; P \ 0.001; Fig. 1). The sub-maximal leptin dose
(40 ng/ml) was chosen for subsequent experiments.
Distribution in the cell cycle (flow cytometry)
Figure 2 presents the distribution of cells in the various
phases of the cell cycle. In the controls, most OVCAR-3
cells were in the G0/G1 phase at any given point of time.
At 48 h, significantly different percentages of cells were in
the S phase (DNA content 2–4n; 13.16 ± 0.40 % for lep-
tin-treated cells vs. 10.99 ± 0.28 % for the control) and
G2 ? M phase (4n; 22.76 ± 0.38 for leptin-treated cells
vs. 20.08 ± 0.62 % for the control) (P \ 0.05; Fig. 2a, b).
Cell cycle gene expression analysis
A 1.2- to 1.9-fold induction of G1/S-specific cyclin D1
(CCND1), G2/mitosis-specific cyclin A2 (CCNA2), tran-
scription factors E2F3 (E2F3), and proliferating cell
nuclear antigen (PCNA) (all genes inducing cell prolifer-
ation) was measured in cells exposed to leptin. In parallel,
1.9- and 1.2-fold suppressions of cyclin-dependent kinase
inhibitor p21 (P21CIP1) and p27 (P27KIP1), respectively,
and a 1.2-fold suppression of growth arrest and DNA-
damage-inducible protein GADD45 alpha (GADD45A)
(genes inhibiting proliferation) were observed. No change
was found in the levels of cell division protein kinases 1
(CDK1), 4 (CDK4), and 6 (CDK6), wee1-like protein
kinase (WEE1), or transcription factors E2F1 (E2F1) or
E2F2 (E2F2). We also noted no change in the levels of the
S-phase regulatory protein cyclin E (CCNE2, CCNE2) or
its partner protein CDK2 (CDK2), or in G2/mitotic-specific
cyclin B1 (CCNB1) (P \ 0.05, P \ 0.001; Table 1).
Cell cycle protein expression analysis
The protein expression of CCND1, CCNA2, and P21CIP1,
the most changed genes during the cell cycle, was analyzed
by western blot. As with the genes’ expression, an increase
in cyclin D1 (an S-phase-associated protein) and cyclin A2
(a G2/M-phase-associated protein) and a decrease in
p21WAF1/CIP1 (inhibitor of S-phase-associated protein)
expression following leptin treatment were noted
(P \ 0.01, P \ 0.001; Fig. 3a–c).
Apoptosis analysis by DNA fragmentation
The statistically significant inhibition of DNA fragmenta-
tion to 84, 82, 75, and 74 % of control values was observed
with leptin treatments of 2, 20, 40, and 100 ng/ml,
respectively (P \ 0.05, P \ 0.01; Fig. 4).
Apoptotic gene expression analysis
As shown in Table 2, leptin had no effect on FAS, CRADD,
caspase 2 (CASP2), or caspase 8 (CASP8) mRNA levels,
whereas we observed 1.4- to 1.8-fold suppression of
TNFR1, FADD, and caspase 10 (CASP10). These results
suggest a lack of activation of the Fas-dependent apoptotic
pathway and inhibition of the TNFR apoptotic pathways.
All of these genes are involved in the extrinsic apoptotic
pathway. A 1.2-fold suppression of caspase 9 (CASP9) and































Fig. 2 Effects of leptin (40 ng/ml) on cellular DNA content and cell
proliferation. a Representative histograms as estimated by flow
cytometry after propidium iodide staining. G0/G1 resting phase, in
preparation for S; S DNA synthesis phase; G2 ? M cells in gap 2 and
entering into the mitotic phase; A apoptotic cells. Arrows indicate
peaks of S and G2 ? M cells. b Relative percentages of the cell
population in S and G2/M phase are presented in the total gated cell
numbers. Values are mean ± SEM. *Significantly different from the
control at P \ 0.05
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protein Apaf-1 (APAF1) were noted. In addition, we
measured a range of 1.3- to 2.2-fold suppression of casp-
ases 3 (CASP3), 6 (CASP6), and 7 (CASP7), which are
well-known effector caspases, and CAD and ICAD, which
are responsible for DNA fragmentation (all of these genes
are involved in the intrinsic apoptotic pathway). Leptin
had no effect on BCL2, BCLW, BCLX, or MCL1 levels
(pro-survival genes), whereas a range of 1.2- to 2.1-fold
suppression of BAD, BAX, BAK1, BID, and BOK (pro-
apoptotic genes) was observed. We also noted no change in
the levels of the endonuclease G (ENDOG) genes involved
in CAD-independent DNA fragmentation or in the tumor-
suppressor gene p53 (TP53) (P \ 0.05, P \ 0.01,
P \ 0.001; Table 2).
Apoptotic protein expression analysis
The protein expression of BAD, TNFR1, and CASP6, the
apoptotic genes that showed the largest changes in gene
expression level, was analyzed by western blot. Leptin-
induced inhibition of Bad (a component of the intrinsic
pathway and a pro-apoptotic Bcl-2 family protein;
P \ 0.001; Fig. 5b), TNFR1 (a component of the extrinsic
pathway, tumor necrosis factor receptor 1; P \ 0.001;
Fig. 5a), and caspase 6 protein (executor caspases;
P \ 0.001; Fig. 5c) expression was noted. The cleaved
forms of caspase 6 were almost undetectable following
leptin treatment.
Discussion
We evaluated the effects of leptin on cell proliferation and
apoptosis in the human ovarian cancer cell line OVCAR-3.
Because we found a dose-dependent stimulatory effect on
cell proliferation and an inhibitory effect on apoptosis, we
expected that the gene products involved in these processes
would also be affected.
Table 1 Changes in selected cell cycle genes’ expression in OVCAR-3 cells exposed to 40 ng/ml leptin for 24 h
Assay ID Transcript Description Gene symbol Average fold change
G1/S phase
100844 ENST00000227507 G1/S-specific cyclin-D1 (PRAD1 oncogene) CCND1 1.3*
102813 ENST00000372991 G1/S-specific cyclin-D3 CCND3 1.0
101418 ENST00000257904 Cell division protein kinase 4 CDK4 1.0
101427 ENST00000265734 Cell division protein kinase 6 CDK6 1.0
100848 ENST00000262643 G1/S-specific cyclin-E1 CCNE1 1.0
100850 ENST00000308108 G1/S-specific cyclin-E2 CCNE2 1.0
101416 ENST00000266970 Cell division protein kinase 2 CDK2 1.0
101538 ENST00000267163 Retinoblastoma-associated protein (pRb) RB1 1.0
102827 ENST00000343380 Transcription factor E2F1 (E2F-1) E2F1 1.0
102830 ENST00000361729 Transcription factor E2F2 (E2F-2) E2F2 1.0
102834 ENST00000346618 Transcription factor E2F3 (E2F-3) E2F3 1.2*
101524 ENST00000379160 Proliferating cell nuclear antigen (PCNA) PCNA 1.2*
G2/M phase
102811 ENST00000274026 Cyclin-A2 (cyclin-A) CCNA2 1.3*
101373 ENST00000256442 G2/mitotic-specific cyclin-B1 CCNB1 1.1
101376 ENST00000288207 G2/mitotic-specific cyclin-B2 CCNB2 1.0
101406 ENST00000293968 Cell division control protein 2 homolog CDK1 1.0
102820 ENST00000302506 M-phase inducer phosphatase 1 CDC25A 1.0
102823 ENST00000245960 M-phase inducer phosphatase 2 CDC25B 1.15
102826 ENST00000323760 M-phase inducer phosphatase 3 CDC25C 1.0
102849 ENST00000299613 Wee1-like protein kinase WEE1 1.0
Cell cycle progresion inhibitors
102909 ENST00000244741 Cyclin-dependent kinase inhibitor 1 (p21) P21CIP1 -1.9**
100855 ENST00000228872 Cyclin-dependent kinase inhibitor 1B (cyclin-dependent
kinase inhibitor p27)
P27KIP1 -1.2*
101471 ENST00000370986 Growth arrest and DNA-damage-inducible protein GADD45
alpha (DNA-damage-inducible transcript 1)
GADD45A -1.2*
Values are mean ± SEM. *,** Significantly different from control at P \ 0.5 and P \ 0.001, respectively. Control value = 1.0
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Effects on cell proliferation
Using the alamarBlue test, which is based on the detection
of cellular metabolic activity, we defined a dose-dependent
(from 2 ng/ml to 100 ng/ml) stimulatory effect of leptin on
OVCAR-3 cell proliferation. This observation is in agree-
ment with Uddin et al. [13], who observed a dose-depen-
dent (from 10 ng/ml) stimulatory effect of leptin on
proliferation of the ovarian epithelial cancer cell line
MDAH2774. On the other hand, Choi et al. [11] showed
that leptin at 1 and 10 ng/ml doses has no effect on human
ovarian cancer BG-1 cell proliferation, but stimulates cell
proliferation at doses of 100 and 1,000 ng/ml.
Flow cytometry analysis showed that leptin promotes
cell cycle progression, as demonstrated by an increased cell
population in both the S and G2/M phases. Our results are
consistent with Catalano et al. [16], who noted an increased
number of Ishikawa human endometrial cancer cells in the
S phase after 24 h of leptin treatment (100 and 1,000 ng/
ml). In addition, Chen et al. [17] observed that 48-h
treatment of ZR-75-1 breast cancer cells with leptin
(100 ng/ml) increases the cell population in both S and G2/
M phases.
Alterations of the mechanisms controlling cell cycle pro-
gression play a relevant role in the pathogenesis of different
human neoplasias. Because the cell cycle is regulated by the
coordinate action of cyclin-dependent kinases (cdks), specific
cyclin proteins, and cdk inhibitors, we focused on the analysis
of cell cycle-associated genes to gain insight into the mech-
anism of leptin’s proliferative action. Using real-time PCR,
we found that leptin (40 ng/ml) impacts proliferation by up-
regulating cell cycle progression genes and suppressing cell
cycle inhibitor genes. We observed up-regulation of mRNAs
for CCND1, CCNA2, PCNA, and E2F3 (genes responsible for
inducing cell proliferation) and down-regulation of mRNAs
for P21CIP1, P27KIP1, and GADD45A (genes responsible
for inhibiting proliferation). Up-regulation of CCND1 and
CCNA2 and down-regulation of P21CIP1, the most changed
genes, were also observed at the protein level by western blot.
Cyclin D1, an important cell cycle regulator, is required for
completion of the G1/S transition in normal mammalian cells
[18, 19] and is one of the most commonly affected proteins in
abnormal states, such as cancer. Our results are consistent
with previous studies showing similar leptin induction of
cyclin D1 expression in human breast cancer [16, 17, 20], the
Fig. 3 Effects of leptin (40 ng/ml) on a cyclin D1 (36 kDa), b cyclin
A (55 kDa), and c p21WAF1/CIP1 (21 kDa) protein expression in
OVCAR-3 cells. Cells were treated with leptin for 24 and 48 h. b-
actin (42 kDa) served as the loading control, and densitometry values
of cyclin D1, cyclin A, and p21WAF1/CIP1 bands were normalized to
b-actin. Signal intensities are expressed in arbitrary units. The values
are mean ± SEM. **,***Significantly different from control at
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** **
Fig. 4 Effects of leptin on DNA fragmentation in OVCAR-3 cells.
Cells were treated with leptin at 2, 20, 40, and 100 ng/ml for 24 h and
then analyzed with a Cellular DNA Fragmentation ELISA kit. RAU,
relative absorbance units. Values are mean ± S.E.M. *,**Signifi-
cantly different from control at P \ 0.05 and P \ 0.01, respectively
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colon cancer cell line HT-29 [21], and human hepatocarci-
noma cells [22]. As cells progress into the S phase, cyclin A is
expressed and becomes the primary cyclin associated with
cdk2. Overexpression of cyclin A has been indicated in var-
ious human tumors, including breast [23], prostate [24], and
ovarian cancer [25, 26]. To the best of our knowledge, this is
the first report of leptin induction of cyclin A expression in
human ovarian cancer cells. In the present study, we observed
suppression of p21WAF1/CIP1, which acts as a universal
inhibitor of cdks, and arrests the cell cycle at both G1/S and
G2/M restriction points [27]. Our results are consistent with
previous studies showing a similar decrease in p21WAF1/
CIP1 expression under the influence of leptin in human breast
cancer cells [17] and Ishikawa human endometrial cancer
cells [16]. Furthermore, low levels of p21WAF1/CIP1 have
been shown to be a marker of poor overall survival in ovarian
cancer patients [28]. Down-regulation or inactivation of the
cdk inhibitors, including p21CIP1, p27KIP1, and p16INK4a,
which normally cause G1 arrest by binding to cyclin-cdk
complexes, is often observed in a variety of human tumors,
rendering the cell susceptible to uncontrolled extracellular
proliferation signals [29].
Table 2 Changes in selected apoptotic genes’ expression in OVCAR-3 cells following exposure to 40 ng/ml leptin for 24 h
Assay ID Transcript Description Gene symbol Average fold
change
Extrinsic pathway
102679 ENST00000162749 Tumor necrosis factor receptor superfamily member 1A precursor
(p60)
TNFR1 -1.8***
100426 ENST00000371875 Tumor necrosis factor receptor superfamily member 6 precursor
(FASLG receptor)
FAS -1.1
100417 ENST00000301838 Protein FADD (FAS-associated death domain protein) FADD -1.54**
100289 ENST00000332896 Death domain-containing protein CRADD (caspase and RIP adapter
with death domain)
CRADD 1.0
100227 ENST00000358485 Caspase-8 precursor CASP8 -1.1
100204 ENST00000272879 Caspase-10 precursor CASP10 -1.45**
100210 ENST00000310447 Caspase-2 precursor CASP2 1.0
Intrinsic pathway
Pro-survival
100083 ENST00000398117 Apoptosis regulator Bcl-2 BCL2 1.0
104039 ENST00000250405 Apoptosis regulator Bcl-W (Bcl-2-like 2 protein) BCLW 1.0
100088 ENST00000307677 Apoptosis regulator Bcl-X (Bcl-2-like 1 protein) BCLX 1.0




104034 ENST00000394532 Bcl2 antagonist of cell death (BAD) BAD -2.1***
100068 ENST00000374467 Bcl-2 homologous antagonist/killer (apoptosis regulator BAK) BAK1 -1.5**
102861 ENST00000293288 Apoptosis regulator BAX BAX -1.3*
100122 ENST00000342111 BH3-interacting domain death agonist (BID) BID -1.2*
100126 ENST00000216115 Bcl-2-interacting killer (Apoptosis inducer NBK) BIK 1.0
100165 ENST00000318407 Bcl-2-related ovarian killer protein (Hbok) BOK -1.8***
100233 ENST00000333868 Caspase-9 precursor CASP9 -1.2*
102892 ENST00000333991 Apoptotic protease-activating factor 1 (Apaf-1) APAF1 -1.8***
100213 ENST00000308394 Caspase-3 precursor CASP3 -1.3*
100222 ENST00000265164 Caspase-6 precursor CASP6 -2.0***
100224 ENST00000369331 Caspase-7 precursor CASP7 -1.5**
102620 ENST00000264705 CAD protein CAD -1.25*




102632 ENST00000372642 Endonuclease G, mitochondrial precursor ENDOG 1.0
101277 ENST00000396473 Cellular tumor antigen p53 (Tumor suppressor p53) TP53 1.0
Values are mean ± SEM. *,**,*** Significantly different from control at P \ 0.05, P \ 0.01, and P \ 0.001, respectively. Control value = 1.0
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To summarize, we suggest that leptin may promote
progression from G1 to S phase by stimulating expression
of cyclin D1 and inhibiting that of p21WAF1/CIP1, as well
as progression to the S phase by stimulating the expression
of cyclin A in an ovarian cancer cell line.
Action on cell apoptosis
A perturbation of the balance between cell proliferation
and apoptosis has been suggested to play a significant role
in mediating tumor progression. Surprisingly, data con-
cerning the anti-apoptotic actions of leptin in ovarian
cancer cells are limited. Herein, we observed that leptin
inhibits OVCAR-3 cell apoptosis in a dose-dependent
manner, as measured by DNA fragmentation. To our
knowledge, there has been only one study addressing leptin
in ovarian cancer cells [13], which showed that 100 ng/ml
of leptin significantly prevents serum-starved apoptosis in
the ovarian epithelial cancer cell lines SKOV-3 and
MDAH2774. In previously published data, using physio-
logically relevant ovarian tissue, we illustrated the inhibi-
tory action of leptin on cell apoptosis in pig ovarian
follicles [30] and the developing corpus luteum [31]. There
are also data showing an anti-apoptotic effect of leptin in
breast cancer cell lines [7].
Cells undergo apoptosis through two major pathways:
the extrinsic (death receptor) pathway and the intrinsic
(mitochondrial) pathway. A hallmark of apoptosis is frag-
mentation of nuclear DNA. This process involves the
caspase 3-dependent DNase CAD or can occur indepen-
dently of caspase activity. In the present study, we found
that 40 ng/ml of leptin acts by suppressing the expression
of pro-apoptotic genes, such as TNFR1, FADD, CASP3, 6,
7, 9, and 10, CAD, ICAD, BAX, BAD, BAK1, BID, BOK,
and APAF1. TNFR1, BAD, and CASP6 were the most
down-regulated genes, and these changes were also
observed at the protein level, as measured by western blot.
Using a gene microarray, Perera et al. [32] observed that in
MCF-7 cells, leptin (500 ng/ml) induces the expression of
anti-apoptotic genes BCL2 and survivin and reduces the
expression of other apoptotic genes (TRAF-interacting
protein and TRADD) involved in the tumor necrosis factor
(TNF)-induced apoptotic pathway. Their observation is
partially consistent with our results, suggesting that leptin
suppresses the TNF-induced extrinsic apoptosis pathway.
Our data further showed suppression of TNFR1 at both the
gene and protein expression levels. The leptin-induced
reduction of Bax protein expression in T47-D breast cancer
cells observed by Nkhata et al. [33], and in BAX gene
expression observed here in OVCAR-3 cells, suggests that
leptin also acts on the intrinsic apoptotic pathway. Down-
regulation of TGFB1-induced Bax expression in hepato-
carcinoma cells was described by Chen et al. [22]. Both
apoptotic pathways lead to activation of the executioner
caspases, caspase 3, 6, and 7, which are the main proteases
degrading the cell. To the best of our knowledge, we are
the first to show down-regulation of caspase 6 (executor
caspase) at the gene and protein levels. Jiang et al. [34]
showed leptin suppression of docetaxel-induced apoptosis
in MCF-7 breast cancer cells via inhibition of caspase 9
activity, indirectly confirming our results. Similar to cas-
pase 6, we observed inhibition of caspase 3 and caspase 7
mRNA expression by leptin, suggesting that leptin inhibits
caspase-dependent apoptosis. Thus, we suggest that leptin
Fig. 5 Effects of leptin (40 ng/ml) on a Bad (23 kDa), b TNFR1
(55 kDa), and c caspase 6 (35, 15 kDa) protein expression in
OVCAR-3 cells. Cells were treated with leptin for 24 and 48 h. b-
actin (42 kDa) served as the loading control, and densitometry of
TNFR1, Bad, and caspase 6 bands were normalized to b-actin. Signal
intensities are expressed in arbitrary units. Values are mean ± SEM.
***Significantly different from control at P \ 0.001
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prevents caspase-dependent apoptosis in OVCAR-3 cells
by down-regulating pro-apoptotic proteins in both extrinsic
(TNFR1) and intrinsic (BAD, caspase 6) apoptosis
pathways.
In conclusion, our results are the first to demonstrate the
molecular mechanism involved in the regulation of the cell
cycle and apoptosis by leptin in an epithelial ovarian
cancer cell line. The combination of proliferative and anti-
apoptotic effects, by up-regulating genes and proteins
responsible for inducing cell proliferation as well as down-
regulating pro-apoptotic genes and proteins in the apoptotic
pathways, clarifies the role of leptin signaling in the pro-
gression of ovarian cancer. Taking into consideration the
limitations of in vitro studies, in vivo studies should be
performed to confirm leptin’s contribution to ovarian can-
cer progression.
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